Executive Summary
Nordson reported 3.8% revenue growth to $2.79 billion in fiscal 2025, driven primarily by the Atrion acquisition, while organic sales declined 2.5%. Net income rose 3.7% to $484 million, supported by margin stability, a lower tax rate, and share repurchases, though interest expense increased 17% due to acquisition debt.
What happened
Nordson generated $2.79 billion in revenue for fiscal 2025, up 3.8% year-over-year, though organic sales declined 2.5% as weak demand in polymer processing and industrial coatings offset strength in electronics dispense and nonwovens. Acquisitions, primarily Atrion in the Medical and Fluid Solutions segment, contributed 6.0% to growth. Gross margin held steady at 55.2%, while operating profit expanded 5.6% to $712 million. Net income increased 3.7% to $484 million despite a 17% rise in interest expense from acquisition-related debt. The company divested its medical contract manufacturing business in the fourth quarter, recording $12.5 million in related charges. Cash flow from operations reached $719 million, up 29%, enabling aggressive capital deployment: $306 million in share repurchases, $224 million in debt paydown, and $179 million in dividends. The effective tax rate dropped 130 basis points to 18.9% due to favorable valuation allowance adjustments.
Why it matters for investors
The results reveal a bifurcated operating environment—acquisition-driven growth masking organic weakness in half the business. The 2.5% organic decline signals demand headwinds in industrial end markets, particularly polymer processing (IPS segment) and medical contract manufacturing (MFS segment, now exited). However, the company's pricing power and mix management preserved gross margins at 55.2%, indicating structural resilience. The Advanced Technology Solutions segment's 180-basis-point margin expansion to 23.5% on positive organic growth demonstrates operating leverage in higher-value electronics applications. Strong cash conversion—operating cash flow up 29% to $719 million—reflects disciplined working capital management and allowed the company to execute a balanced capital allocation strategy: reducing debt, repurchasing shares, and sustaining dividends. The $306 million in buybacks partially offset dilution from stock-based compensation and reduced share count, contributing to 5.0% EPS growth despite only 3.7% net income growth. Rising interest expense ($15 million year-over-year) from acquisition debt highlights the ongoing cost of inorganic expansion, though management demonstrated willingness to delever with $224 million in debt reduction. The divestiture of the medical contract manufacturing business suggests portfolio optimization, shedding lower-margin operations to improve profitability mix. However, execution risks remain around integrating Atrion while navigating trade policy uncertainty, tariffs, and currency volatility—factors management explicitly flagged as material.
Bullish points
Operating cash flow surged 29% to $719 million, demonstrating strong cash conversion and enabling $306 million in share buybacks and $224 million in debt reduction—indicating financial flexibility despite organic headwinds.
Advanced Technology Solutions segment delivered 180-basis-point margin expansion to 23.5% on 4.1% organic growth, driven by robust demand in electronics dispense applications and cost discipline—highlighting operating leverage in higher-value markets.
Effective tax rate improved 130 basis points to 18.9% due to favorable valuation allowance adjustments, providing a sustainable earnings tailwind.
Gross margin stability at 55.2% despite organic sales decline reflects pricing power and favorable mix, suggesting structural profitability resilience.
Divestiture of the medical contract manufacturing business removes lower-margin operations, potentially improving future profitability mix in the Medical and Fluid Solutions segment.
Bearish points
Organic sales declined 2.5%, with Industrial Precision Solutions down 5.1% and Medical and Fluid Solutions down 3.1%, indicating weak end-market demand in polymer processing, industrial coatings, and medical contract manufacturing.
Interest expense rose $15 million (17%) year-over-year to $104 million, reflecting higher debt levels from the Atrion acquisition and compressing net margins despite operational gains.
Industrial Precision Solutions EBITDA margin declined 10 basis points to 37.1% on lower volumes, suggesting limited operating leverage on the downside.
Two-thirds of revenue (67%) generated internationally exposes the company to currency volatility, trade policy uncertainty, and tariff risks explicitly flagged by management as material.
Approximately 71% of cash held at foreign subsidiaries creates potential repatriation complexity and tax consequences if needed for U.S. obligations.
Key highlights
Nordson operates a diversified precision dispensing and coating equipment business across industrial, medical, and electronics end markets. Fiscal 2025 results reflected acquisition-led growth (+6.0% from deals) offsetting organic weakness (-2.5%), with consolidated revenue reaching $2.79 billion. The company maintained gross margin discipline at 55.2% and expanded operating profit 5.6% to $712 million, though organic sales declined across two of three segments. Advanced Technology Solutions was the operational bright spot, expanding EBITDA margin 180 basis points to 23.5% on 4.1% organic growth driven by electronics dispense demand. Industrial Precision Solutions faced headwinds with 5.1% organic decline in polymer processing and coatings, while Medical and Fluid Solutions divested its contract manufacturing business. Strong operating cash flow of $719 million (+29%) funded balanced capital allocation: $306 million in buybacks, $224 million in debt reduction, and $179 million in dividends. The effective tax rate improved 130 basis points to 18.9%, supporting 5.0% EPS growth to $8.51 despite only 3.7% net income growth. Management highlighted material risks from trade policy uncertainty, tariffs, currency fluctuations, and cybersecurity threats. The company ended the year with $108 million in cash, $265 million outstanding on a term loan facility, and $135 million on a revolving credit facility, with $935 million in available borrowing capacity.
Management commentary
Management stated that the company is well-positioned to manage liquidity needs from working capital, capital expenditures, pension obligations, debt service, dividends, and share repurchases. Primary sources of capital include $108 million in cash on hand, $719 million in operating cash flow, and $935 million in available borrowing capacity as of October 31, 2025. Management expressed confidence that cash from operations combined with borrowing capacity and capital market access is expected to be more than adequate to fund liquidity needs over the twelve months and foreseeable future. However, management cautioned that changes in trade policies, tariffs, and import/export regulations could negatively impact cash flow and liquidity in future periods. Management noted commitment to identifying, developing, and retaining key employees to ensure uninterrupted leadership through organizational changes including acquisitions, divestitures, and realignments. Regarding the divestiture of the medical contract manufacturing business, management incurred $12.5 million in related charges during the fourth quarter.
What to watch next
Investors should monitor:
Organic sales trajectory in the Industrial Precision Solutions segment, particularly polymer processing and industrial coatings product lines, to assess whether demand stabilizes or deteriorates further.
Integration progress and profitability contribution from the Atrion acquisition in the Medical and Fluid Solutions segment, given the 23% revenue contribution from acquisitions.
Debt reduction pace and interest expense trends as management balances deleveraging with ongoing capital deployment for buybacks and dividends.
Impact of trade policy changes, tariff adjustments, and currency volatility on profitability, given 67% international revenue exposure and explicit management warnings.
Advanced Technology Solutions segment margin sustainability at 23.5% EBITDA margin as management seeks to maintain operating leverage on organic growth in electronics markets.
This summary is based solely on excerpts from the company's Form 10-K filing.